Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

[1]  M. Buti,et al.  Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. , 2015, Journal of hepatology.

[2]  K. Reddy,et al.  GrazoprevirElbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection , 2015, Annals of Internal Medicine.

[3]  Brad J. Wood,et al.  Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. , 2015, JAMA.

[4]  T. Pilot‐Matias,et al.  Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. , 2015, JAMA.

[5]  J. Rockstroh,et al.  Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study , 2015, The Lancet.

[6]  H. Razavi,et al.  Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.

[7]  A. Mocroft,et al.  HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective , 2014, BMC Infectious Diseases.

[8]  K. Mounzer,et al.  Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. , 2014, JAMA.

[9]  S. Braunstein,et al.  Deaths among people with hepatitis C in New York City, 2000-2011. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  A. Localio,et al.  Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C VirusMonoinfected Patients , 2014, Annals of Internal Medicine.

[11]  Richard D Moore,et al.  Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: Prospective analysis of 435 liver biopsy pairs , 2014, Hepatology.

[12]  J. Slim,et al.  Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens , 2014, Journal of the International AIDS Society.

[13]  A. Mocroft,et al.  Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? , 2013, Journal of hepatology.

[14]  L. Taylor,et al.  HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  K. Lacombe,et al.  HIV and viral hepatitis coinfections: advances and challenges , 2012, Gut.

[16]  A. Mocroft,et al.  Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. , 2008, The Journal of infectious diseases.

[17]  M. Peters,et al.  Viral hepatitis in HIV infection. , 2007, The New England journal of medicine.

[18]  Harpreet K. Monga,et al.  Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  M. Saag.  Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1 , 2016 .